And with no admitted fault or failure, I'm delighted that we've also drawn a line under the vast majority of Zantac litigation ... about that. But it looks like the decline in vaccine efficacy ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves.

That may not imply a ‘Truss’ like crisis but does portend higher interest rates than would otherwise be the case. Bond rates set the price for fixed rate mortgage deals so homeowners look as ...

Within these costs we have included the likely payouts related to the increasingly concerning Zantac litagation ... acquisition looks like an overpayment, but it does give Sanofi entry into ...

Gordon Brown may have tested everyone's patience but one can never imagine him delivering anything as challenging to the ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

GSK said total sales fell by two per cent in the third quarter Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and ...

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in ...